A Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE)
Brief description of study
This study aims to determine the effect of two dose strengths of dalfampridine-ER (AMPYRA) on adult patients who have experienced an ischemic stroke and continue to have stable walking issues.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Stroke
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
06 Apr 2017.
Study ID: 821208
